nodes	percent_of_prediction	percent_of_DWPC	metapath
Mimosine—TYR—skin cancer	0.915	1	CbGaD
Mimosine—TYR—skin epidermis—skin cancer	0.0113	0.148	CbGeAlD
Mimosine—TYR—hair follicle—skin cancer	0.00809	0.106	CbGeAlD
Mimosine—CCL2—skin epidermis—skin cancer	0.00651	0.0852	CbGeAlD
Mimosine—CCL2—endothelium—skin cancer	0.00472	0.0618	CbGeAlD
Mimosine—CCL2—blood vessel—skin cancer	0.00436	0.057	CbGeAlD
Mimosine—TYR—skin of body—skin cancer	0.00351	0.0459	CbGeAlD
Mimosine—SHMT1—nipple—skin cancer	0.0034	0.0445	CbGeAlD
Mimosine—CCL2—nipple—skin cancer	0.00315	0.0412	CbGeAlD
Mimosine—CCL2—neck—skin cancer	0.00312	0.0408	CbGeAlD
Mimosine—TYR—lymphoid tissue—skin cancer	0.00284	0.0372	CbGeAlD
Mimosine—TYR—head—skin cancer	0.00229	0.03	CbGeAlD
Mimosine—CCL2—connective tissue—skin cancer	0.00223	0.0292	CbGeAlD
Mimosine—CCL2—epithelium—skin cancer	0.00212	0.0277	CbGeAlD
Mimosine—CCL2—skin of body—skin cancer	0.00202	0.0264	CbGeAlD
Mimosine—SHMT1—mammalian vulva—skin cancer	0.00198	0.026	CbGeAlD
Mimosine—CCL2—mammalian vulva—skin cancer	0.00184	0.0241	CbGeAlD
Mimosine—SHMT1—lymphoid tissue—skin cancer	0.00176	0.0231	CbGeAlD
Mimosine—SHMT1—female reproductive system—skin cancer	0.0017	0.0222	CbGeAlD
Mimosine—CCL2—lymphoid tissue—skin cancer	0.00163	0.0214	CbGeAlD
Mimosine—TYR—lymph node—skin cancer	0.0016	0.021	CbGeAlD
Mimosine—CCL2—female reproductive system—skin cancer	0.00158	0.0206	CbGeAlD
Mimosine—SHMT1—head—skin cancer	0.00142	0.0186	CbGeAlD
Mimosine—CCL2—head—skin cancer	0.00132	0.0172	CbGeAlD
Mimosine—SHMT1—lymph node—skin cancer	0.000994	0.013	CbGeAlD
Mimosine—CCL2—lymph node—skin cancer	0.000922	0.0121	CbGeAlD
Mimosine—CCL2—Spinal Cord Injury—CSPG4—skin cancer	0.0005	0.0552	CbGpPWpGaD
Mimosine—CCL2—Peptide ligand-binding receptors—MC1R—skin cancer	0.000326	0.0359	CbGpPWpGaD
Mimosine—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—skin cancer	0.00032	0.0353	CbGpPWpGaD
Mimosine—SHMT1—Validated targets of C-MYC transcriptional activation—TERT—skin cancer	0.000308	0.034	CbGpPWpGaD
Mimosine—CCL2—Ectoderm Differentiation—SHH—skin cancer	0.0003	0.0331	CbGpPWpGaD
Mimosine—SHMT1—Validated targets of C-MYC transcriptional activation—CDK4—skin cancer	0.000276	0.0304	CbGpPWpGaD
Mimosine—CCL2—GMCSF-mediated signaling events—NRAS—skin cancer	0.000233	0.0257	CbGpPWpGaD
Mimosine—CCL2—GPCR ligand binding—PTCH2—skin cancer	0.00023	0.0254	CbGpPWpGaD
Mimosine—CCL2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000219	0.0241	CbGpPWpGaD
Mimosine—CCL2—GMCSF-mediated signaling events—KRAS—skin cancer	0.0002	0.0221	CbGpPWpGaD
Mimosine—CCL2—AP-1 transcription factor network—CDKN2A—skin cancer	0.000192	0.0212	CbGpPWpGaD
Mimosine—CCL2—Metabolism of proteins—EXOC2—skin cancer	0.00019	0.021	CbGpPWpGaD
Mimosine—SHMT1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	0.000182	0.0201	CbGpPWpGaD
Mimosine—CCL2—GMCSF-mediated signaling events—HRAS—skin cancer	0.00017	0.0188	CbGpPWpGaD
Mimosine—CCL2—GPCR ligand binding—MC1R—skin cancer	0.000166	0.0184	CbGpPWpGaD
Mimosine—CCL2—Spinal Cord Injury—CDK4—skin cancer	0.000166	0.0183	CbGpPWpGaD
Mimosine—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—skin cancer	0.000163	0.018	CbGpPWpGaD
Mimosine—CCL2—IL23-mediated signaling events—IL6—skin cancer	0.000163	0.018	CbGpPWpGaD
Mimosine—CCL2—Selenium Micronutrient Network—PTGS2—skin cancer	0.00015	0.0165	CbGpPWpGaD
Mimosine—CCL2—TWEAK Signaling Pathway—IL6—skin cancer	0.000147	0.0163	CbGpPWpGaD
Mimosine—CCL2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000144	0.0159	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—RHOU—skin cancer	0.000143	0.0158	CbGpPWpGaD
Mimosine—SHMT1—Folate Metabolism—TP53—skin cancer	0.000135	0.0149	CbGpPWpGaD
Mimosine—CCL2—Oncostatin M Signaling Pathway—KRAS—skin cancer	0.000128	0.0141	CbGpPWpGaD
Mimosine—CCL2—Vitamin B12 Metabolism—IL6—skin cancer	0.000126	0.0139	CbGpPWpGaD
Mimosine—SHMT1—Folate Metabolism—IL6—skin cancer	0.000124	0.0137	CbGpPWpGaD
Mimosine—CCL2—GPCR ligand binding—SHH—skin cancer	0.000119	0.0131	CbGpPWpGaD
Mimosine—CCL2—Spinal Cord Injury—PTGS2—skin cancer	0.000118	0.0131	CbGpPWpGaD
Mimosine—CCL2—Signaling by GPCR—PTCH2—skin cancer	0.000118	0.013	CbGpPWpGaD
Mimosine—SHMT1—Validated targets of C-MYC transcriptional activation—TP53—skin cancer	0.000117	0.0129	CbGpPWpGaD
Mimosine—CCL2—Oncostatin M Signaling Pathway—TP53—skin cancer	0.000114	0.0125	CbGpPWpGaD
Mimosine—CCL2—GPCR ligand binding—SMO—skin cancer	0.000112	0.0124	CbGpPWpGaD
Mimosine—CCL2—GPCR ligand binding—PTCH1—skin cancer	0.000112	0.0124	CbGpPWpGaD
Mimosine—CCL2—TNF alpha Signaling Pathway—NRAS—skin cancer	0.000112	0.0124	CbGpPWpGaD
Mimosine—CCL2—Folate Metabolism—TP53—skin cancer	0.000112	0.0124	CbGpPWpGaD
Mimosine—CCL2—GPCR ligand binding—PTGER4—skin cancer	0.000109	0.0121	CbGpPWpGaD
Mimosine—CCL2—Oncostatin M Signaling Pathway—HRAS—skin cancer	0.000109	0.012	CbGpPWpGaD
Mimosine—CCL2—AP-1 transcription factor network—TP53—skin cancer	0.000107	0.0118	CbGpPWpGaD
Mimosine—CCL2—Folate Metabolism—IL6—skin cancer	0.000103	0.0113	CbGpPWpGaD
Mimosine—CCL2—AP-1 transcription factor network—IL6—skin cancer	9.79e-05	0.0108	CbGpPWpGaD
Mimosine—CCL2—TNF alpha Signaling Pathway—KRAS—skin cancer	9.67e-05	0.0107	CbGpPWpGaD
Mimosine—SHMT1—Metabolism—PLIN2—skin cancer	9.47e-05	0.0104	CbGpPWpGaD
Mimosine—SHMT1—Disease—CSPG4—skin cancer	9.11e-05	0.0101	CbGpPWpGaD
Mimosine—CCL2—Signaling by GPCR—MC1R—skin cancer	8.54e-05	0.00942	CbGpPWpGaD
Mimosine—CCL2—TNF alpha Signaling Pathway—HRAS—skin cancer	8.22e-05	0.00907	CbGpPWpGaD
Mimosine—CCL2—Selenium Micronutrient Network—IL6—skin cancer	8.15e-05	0.009	CbGpPWpGaD
Mimosine—CCL2—TNF alpha Signaling Pathway—IL6—skin cancer	7.87e-05	0.00868	CbGpPWpGaD
Mimosine—SHMT1—Metabolism—CSPG4—skin cancer	7.63e-05	0.00842	CbGpPWpGaD
Mimosine—CCL2—Spinal Cord Injury—TP53—skin cancer	7.04e-05	0.00777	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—PTCH2—skin cancer	6.98e-05	0.0077	CbGpPWpGaD
Mimosine—CCL2—Spinal Cord Injury—IL6—skin cancer	6.45e-05	0.00711	CbGpPWpGaD
Mimosine—SHMT1—Disease—ENO2—skin cancer	6.2e-05	0.00683	CbGpPWpGaD
Mimosine—SHMT1—Disease—SHH—skin cancer	6.2e-05	0.00683	CbGpPWpGaD
Mimosine—CCL2—Signaling by GPCR—SHH—skin cancer	6.09e-05	0.00671	CbGpPWpGaD
Mimosine—CCL2—Signaling by GPCR—SMO—skin cancer	5.77e-05	0.00636	CbGpPWpGaD
Mimosine—CCL2—Signaling by GPCR—PTCH1—skin cancer	5.77e-05	0.00636	CbGpPWpGaD
Mimosine—CCL2—Signaling by GPCR—PTGER4—skin cancer	5.62e-05	0.0062	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—GLI2—skin cancer	5.29e-05	0.00583	CbGpPWpGaD
Mimosine—SHMT1—Metabolism—ENO2—skin cancer	5.19e-05	0.00572	CbGpPWpGaD
Mimosine—SHMT1—Disease—FOXO4—skin cancer	5.05e-05	0.00557	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—MC1R—skin cancer	5.05e-05	0.00557	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—GLI1—skin cancer	4.97e-05	0.00549	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—SUFU—skin cancer	4.71e-05	0.0052	CbGpPWpGaD
Mimosine—SHMT1—Disease—ERCC2—skin cancer	3.6e-05	0.00397	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—SHH—skin cancer	3.59e-05	0.00397	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—RASA1—skin cancer	3.57e-05	0.00394	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—PTCH1—skin cancer	3.41e-05	0.00376	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—SMO—skin cancer	3.41e-05	0.00376	CbGpPWpGaD
Mimosine—SHMT1—Disease—TERT—skin cancer	3.37e-05	0.00372	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—PTGER4—skin cancer	3.32e-05	0.00366	CbGpPWpGaD
Mimosine—SHMT1—Metabolism—ERCC2—skin cancer	3.01e-05	0.00332	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—FOXO4—skin cancer	2.93e-05	0.00323	CbGpPWpGaD
Mimosine—SHMT1—Disease—BRAF—skin cancer	2.67e-05	0.00295	CbGpPWpGaD
Mimosine—SHMT1—Disease—PTGS2—skin cancer	2.16e-05	0.00238	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—TERT—skin cancer	1.96e-05	0.00216	CbGpPWpGaD
Mimosine—SHMT1—Metabolism—PTGS2—skin cancer	1.81e-05	0.00199	CbGpPWpGaD
Mimosine—SHMT1—Disease—NRAS—skin cancer	1.68e-05	0.00185	CbGpPWpGaD
Mimosine—CCL2—Signaling by GPCR—NRAS—skin cancer	1.65e-05	0.00182	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—BRAF—skin cancer	1.55e-05	0.00171	CbGpPWpGaD
Mimosine—SHMT1—Disease—KRAS—skin cancer	1.44e-05	0.00159	CbGpPWpGaD
Mimosine—CCL2—Signaling by GPCR—KRAS—skin cancer	1.42e-05	0.00157	CbGpPWpGaD
Mimosine—SHMT1—Disease—HRAS—skin cancer	1.23e-05	0.00136	CbGpPWpGaD
Mimosine—CCL2—Signaling by GPCR—HRAS—skin cancer	1.21e-05	0.00133	CbGpPWpGaD
Mimosine—SHMT1—Disease—IL6—skin cancer	1.18e-05	0.0013	CbGpPWpGaD
Mimosine—CCL2—Signaling by GPCR—IL6—skin cancer	1.15e-05	0.00127	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—NRAS—skin cancer	9.74e-06	0.00107	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—KRAS—skin cancer	8.38e-06	0.000925	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—TP53—skin cancer	7.45e-06	0.000822	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—HRAS—skin cancer	7.13e-06	0.000786	CbGpPWpGaD
Mimosine—CCL2—Signaling Pathways—IL6—skin cancer	6.82e-06	0.000753	CbGpPWpGaD
